logo
Share SHARE
FONT-SIZE Plus   Neg

Aduro BioTech Acquires GVAX Assets From BioSante Pharma - Quick Facts

Aduro BioTech Inc. announced the acquisition of all GVAX assets from BioSante Pharmaceuticals Inc. (BPAX), including intellectual property and cell lines.

Aduro previously licensed two GVAX vaccines, GVAX Pancreas and GVAX Prostate, for use in combination with its Listeria-based vaccines.

Aduro said that the new acquisition covers all uses and includes additional vaccines for multiple myeloma and breast and colon cancer and assumes rights to the existing license agreement for GVAX Melanoma.

Under its purchase agreement with BioSante, Aduro paid $1 million upfront and has committed to additional milestone and royalty payments after commercialization of GVAX product(s).

GVAX vaccines are based on human cancer cell lines that are genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune-stimulatory cytokine.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Google is planning to significantly expand a carpool service on its navigational app Waze, according to a report in the Wall Street Journal. The move indicates the company is edging closer to a potential clash with ride-hailing service Uber Technologies Inc. Private equity firm Sycamore Partners has won the bankruptcy auction for the e-commerce business and intellectual property of U.S. women's apparel retailer The Limited with a bid of $26.8 million, Reuters reported, citing people familiar with the matter. A U.S. bankruptcy court judge must now approve the sale to Sycamore Partners. French telecommunications operator Orange SA reported Thursday higher net profit in its fiscal year 2016 mainly on income from discontinued operations. Operating income, meanwhile, declined, despite increased revenues. For fiscal 2017, the company projects higher adjusted EBITDA, a key earnings metric.
comments powered by Disqus
Follow RTT